NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis $1.47 0.00 (0.00%) Closing price 07/17/2026 03:59 PM EasternExtended Trading$1.47 0.00 (-0.20%) As of 07/17/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Purple Biotech Stock (NASDAQ:PPBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Purple Biotech alerts:Sign Up Key Stats Today's Range$1.42▼$1.5550-Day Range$1.41▼$4.0652-Week Range$1.35▼$29.00Volume16,691 shsAverage Volume39,017 shsMarket Capitalization$1.37 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Read More Purple Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePPBT MarketRank™: Purple Biotech scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPurple Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPurple Biotech has a consensus price target of $30.00, representing about 1,940.8% upside from its current price of $1.47.Amount of Analyst CoveragePurple Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Purple Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Purple Biotech are expected to grow in the coming year, from ($5.31) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Purple Biotech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 0.43, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 73.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentPurple Biotech has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by Institutions9.64% of the stock of Purple Biotech is held by institutions.Read more about Purple Biotech's insider trading history. Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPBT Stock News HeadlinesPurple Biotech presents new IM1240 preclinical data showing anti-tumor activity and broad therapeutic window (PPBT)June 12, 2026 | msn.comPurple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic WindowJune 11, 2026 | finance.yahoo.comBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026.July 18 at 1:00 AM | Chaikin Analytics (Ad)Analysts Are Bullish on These Healthcare Stocks: Purple Biotech (PPBT), Satellos Bioscience (MSLE)May 19, 2026 | theglobeandmail.comPurple Biotech Reports First Quarter 2026 Financial Results and Business HighlightsMay 16, 2026 | markets.businessinsider.comPurple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240April 27, 2026 | markets.businessinsider.comPurple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformApril 23, 2026 | markets.businessinsider.comPurple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformMarch 25, 2026 | markets.businessinsider.comSee More Headlines PPBT Stock Analysis - Frequently Asked Questions How have PPBT shares performed this year? Purple Biotech's stock was trading at $6.5750 on January 1st, 2026. Since then, PPBT shares have decreased by 77.6% and is now trading at $1.47. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) announced its earnings results on Saturday, May, 16th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.29. When did Purple Biotech's stock split? Shares of Purple Biotech reverse split on the morning of Monday, March 2nd 2026.The 1-10 reverse split was announced on Wednesday, February 11th 2026. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Purple Biotech IPO? Purple Biotech (PPBT) raised $13 million in an initial public offering (IPO) on Friday, November 20th 2015. The company issued 3,158,900 shares at $4.13 per share. How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Purple Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings5/16/2026Today7/18/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (54m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PPBT's financial health is in the Red zone, according to TradeSmith. PPBT has been in this zone for over 54 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PPBT Previous SymbolNASDAQ:KTOV CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Price Target for Purple Biotech$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+1,940.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($18.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-123.63% Return on Assets-98.72% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.39 per share Price / Book0.14Miscellaneous Outstanding Shares930,000Free Float901,000Market Cap$1.37 million OptionableOptionable Beta0.68 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PPBT) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our Partners‘We are at a hinge point in history’The new Fed chair just told Congress we are at a hinge point in history, signaling tighter policy ahead. When ...Weiss Ratings | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
